Stock Market Reaction: Novo Nordisk's stock fell nearly 10% due to disappointing Alzheimer’s trial results for its Ozempic pill, highlighting the volatility of pharmaceutical stocks based on clinical outcomes.
Investment Screening Tools: The need for reliable screening tools in evaluating pharmaceutical companies is emphasized, with Seeking Alpha’s Quant Ratings system providing a data-driven approach to identify investment opportunities.
Quant Ratings Performance: Seeking Alpha’s model has significantly outperformed the S&P 500, with its recommendations yielding a 1,755% return compared to the S&P's 379% from January 2010 to June 2021.
Top Pharmaceutical Stocks: A list of large-cap pharmaceutical stocks ranked by Seeking Alpha’s Quant metrics includes Pfizer, Bristol-Myers Squibb, and GSK, with varying year-to-date performances and ratings.
Wall Street analysts forecast PJP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PJP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast PJP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PJP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 105.690
Low
Averages
High
Current: 105.690
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
